Aldea raises $24m for alcohol detox, anemia drug
This article was originally published in Scrip
Executive Summary
Aldea Pharmaceuticals will begin clinical trials in acute alcohol intoxication and Fanconi anemia for AD-6626, the company's lead drug candidate for aldehyde metabolism disorders, with $24m in Series B venture capital from new Russian and Chinese investors and existing US-based VC backers.